free counter with statistics

Novavax COVID-19 vaccine research now consists of children, firm says

Get Extra 15% OFF on PureVPN 1-Month Subscription with Coupon Code: 1M15
Get PureVPN

Vaccine growth firm Novavax on Monday introduced it has expanded its Section Three medical trial for its COVID-19 vaccine to youngsters between the ages of 12 and 17. 

The corporate stated it is testing its COVID-19 vaccine —  NVX-CoV2373 — on some 3,000 pediatric sufferers throughout 75 U.S. places. The corporate is testing two doses of its vaccine candidate spaced 21 days aside. 

“Two-thirds of volunteers will obtain intramuscular injections of the vaccine and one-third will obtain placebo. A blinded crossover is deliberate to happen six months after the preliminary set of vaccinations to make sure that all trial individuals obtain lively vaccine,” the corporate stated in a information launch. “Individuals can be monitored for security for as much as two years following the ultimate dose.”

In late January, Novavax introduced its protein-based vaccine confirmed 89.3% efficacy towards coronavirus in a U.Ok.-based trial, which it famous was throughout a peak interval of transmission and when the B.1.1.7 variant was in circulation.


Then, in March, the Maryland-based firm stated its coronavirus candidate in closing analyses proved 96.4% efficient towards COVID-19. The vaccine was additionally discovered to have 86.3% efficacy towards the U.Ok. variant and 48.6% efficacy towards a regarding variant first recognized in South Africa. 

Nevertheless, the jab revealed 100% efficacy towards extreme illness, together with hospitalization and loss of life, in each trials, the ultimate evaluation discovered. 

“We’re very inspired by the information displaying that NVX-CoV2373 not solely supplied full safety towards probably the most extreme types of illness but in addition dramatically lowered delicate and reasonable illness throughout each trials,” Stanley Erck, president and chief government officer of Novavax, stated in an announcement on the time. “Importantly, each research confirmed efficacy towards the variant strains.”


The identical month, Erck additionally predicted that the U.S. Meals and Drug Administration (FDA) may probably grant his firm’s vaccine candidate emergency use authorization as early as Could.

Pending approval, the corporate has agreed to provide the U.S. with 110 million doses, which if the expected timeline holds true could possibly be accomplished round June or July, Erck informed CNBC. 


Vaccine opponents Pfizer and Moderna are additionally testing their COVID-19 vaccine in adolescents, with the FDA anticipated to authorize Pfizer’s COVID-19 vaccine for younger adults age 12 and older by subsequent week, in keeping with a federal official and an individual acquainted with the method, establishing photographs for a lot of earlier than the start of the following college 12 months.

Outcomes are also anticipated by the center of this 12 months from a U.S. research of Moderna’s vaccine in 12- to 17-year-olds.

Fox Information’ Alexandria Hein, Kayla Rivas, and the Related Press contributed to this report. 

Comments are closed.